PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT01387711
- Locations
- 🇩🇪
Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01347255
- Locations
- 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, France
Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris
Completed
- Conditions
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 588
- Registration Number
- NCT01320774
- Locations
- 🇩🇪
University Clinic of Erlangen Nuernberg, Erlangen, Germany
LEO 32731 - A Study in Healthy Male Subjects
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 111
- Registration Number
- NCT01310049
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01297166
- Locations
- 🇫🇷
CPCAD, Nice, France
A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01293357
- Locations
- 🇯🇵
Hakata Clinic LTA Clinical Pharmacology Center, Fukuoka, Japan
A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT01293383
- Locations
- 🇯🇵
Hakata Clinic LTA Clinical Pharmacology Center, Fukuoka, Japan
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.
Completed
- Conditions
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 529
- Registration Number
- NCT01268774
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 21
- Registration Number
- NCT01257919
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services of Nevada Inc., Las Vegas, Nevada, United States
Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 102
- Registration Number
- NCT01229098
- Locations
- 🇨🇦
Alpha Clinical Research Centre, Saint John's, Newfoundland and Labrador, Canada
🇨🇦Dermadvances Research, Winnipeg, Manitoba, Canada
🇨🇦Eastern Canada Cutaneous Research Associates Ltd., Halifax, Nova Scotia, Canada
© Copyright 2024. All Rights Reserved by MedPath